Journal of Clinical Oncology· 2014Q1· Clinical trial
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- 1,632citations
- Q1SCImago
- 2014year
Short summary
Adding bevacizumab to standard chemotherapy significantly improved progression-free survival (PFS) and objective response rate (ORR) in patients with platinum-resistant recurrent ovarian cancer.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Reproductive Medicine
Reproductive MedicineMedicine